This document is a published patent application from the USPTO detailing novel methods and compositions for detecting splice variants of the endoglin protein, which are associated with cancer. The application, identified as US20260086096A1, specifically describes the use of endoglin-specific antibodies to enhance the accuracy and reliability of cancer diagnosis by identifying these variants.

As this is a patent application, it does not impose immediate regulatory obligations on entities. However, it signals potential future developments in diagnostic tools for cancer. Companies involved in diagnostics, antibody development, or cancer research may wish to review the application for insights into emerging technologies and potential intellectual property landscapes. The filing date was September 26, 2025.